Anavex Life Sciences Corp.
AVXLHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeAnavex Life Sciences Corp. operates as a biopharmaceutical company. At a $258.1M market cap, Anavex Life Sciences Corp. ranks as a micro-cap company within healthcare. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer.
Market Cap
$258.1M
Beta
1.25
P/E (TTM)
—
P/E (Fwd)
-5.06
EPS (TTM)
$-0.46
EPS (Fwd)
$-0.55
ROE
-33.6%
ROA
-21.6%
Cash
$131.7M
Total Debt
$0
Free CF
-$21.8M
52W Change
-63.9%
Annual Financials
Cash vs Debt
Anavex Life Sciences Corp. reports $131.7M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$21.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -33.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Anavex Life Sciences Corp.'s trajectory.